A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes

Diabetes Care

Volumn 21, Issue 11, 1998, Pages 1897-1903

  Goldberg, Ronald B ^a   Einhorn, Daniel ^b   Lucas, Charles P ^c   Rendell, Marc S ^d   Damsbo, Peter ^e   Huang, Won Chin ^e   Strange, Poul ^e   Brodows, Robert G ^f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Diabetes and Endocrine Associates   (United States)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

^d Creighton Diabetes Center   (United States)

^e NOVO NORDISK INC   (United States)

^f Vanderbilt Child Development Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CARBAMATES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES;

EID: 0031724919     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.11.1897     Document Type: Article

References (19)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
3. The Diabetes Control and Complications Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117, 1995
5. American Diabetes Association: Clinical Practice Recommendations 1998. Diabetes Care 21 (Suppl. 1):1-98, 1998
6. Andersson DKG, Svardsudd K: Long term glycemic control relates to mortality in type II diabetes. Diabetes Care 18:1534-1543, 1995
7. Uusitupa MIJ, Niskanen LK, Siitonen O, Voutilainen, E, Pyörälä K: Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects, Diabctologia 36:1175-1184, 1993
8. Skyler JS: Diabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am 25:243-254, 1996
9. United Kingdom Prospective Diabetes Study Group: United Kingdom Prospective Diabetes Study (UKPDS) 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 310:83-88, 1995
10. Berger W Caduff F, Pasquel M, Rump A: Die relative Häufigkeit der schweren Sulfonylharnstoff-Hypoglykämie in den letzten 25 Jehren in der Schweiz. Schweiz Med Wochenschr 116:145-151, 1986
11. American Diabetes Association: Physician's Guide to Non-Insulin-Dependent (Type II) Diabetes: Diagnosis and Treatment. 2nd ed. Alexandria, VA: American Diabetes Association, 1988
12. Alberti KGMM, Cries FA: Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabet Med 5:275-281, 1988
13. + concentrations. Pharm Res 32:111-114, 1995
14. Bakkali-Nadi A, Malaisse-Lagae F, Malaisse WJ: Insulinotropic action of meglitinide analogs: concentration-response relationship and nutrient dependency. Diabetes Res 27:81-87, 1994
15. Malaisse WJ: Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: the meglitinide family. Horm Metab Res 27:263-266, 1995
16. Lins L, Brasseur R, Malaisse WJ: Conformational analysis of non-sulfonylurea hypoglycemic agents of the meglitinide family. Biochem Pharma 50:1879-1884, 1995
17. Gromada J, Dissing S, Kofod H, Frøkjaer-Jensen J: Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in β TC3 cells and rat pancreatic beta cells. Diabetologa 38:1025-1032, 1995
18. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay R Shymko R, Carr RD: Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47:345-351, 1998
19. Groop LC: Drug treatment of NIDDM. In Textbook of Diabetes. Vol. 1. Pickup JC, Williams G, Eds. Oxford, U.K., Blackwell, 1996, p. 38.1-38.17